Hillstream BioPharma, Inc.
NASDAQ: HILS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Randy D. Milby MBA
- Employees
- 1
- Headquarters
- Bridgewater, United States
- IPO year
- 2022
- Market cap
- $4.2M
- Website
- https://www.hillstreambio.com
Loading HILS…
Loading profile data…Frequently asked questions about HILS
What does Hillstream BioPharma, Inc. (HILS) do?
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's development...
Where does HILS trade?
Hillstream BioPharma, Inc. (HILS) trades on the NASDAQ Capital Market.
What sector is HILS in?
Hillstream BioPharma, Inc. (HILS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hillstream BioPharma, Inc.?
Randy D. Milby MBA is the chief executive officer of Hillstream BioPharma, Inc. (HILS).
Where is Hillstream BioPharma, Inc. headquartered?
Hillstream BioPharma, Inc. is headquartered in United States.
Does HILS pay a dividend?
Hillstream BioPharma, Inc. (HILS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HILS go public?
Hillstream BioPharma, Inc. (HILS) completed its initial public offering in 2022.